Thomas K. Equels, Executive Vice Chairman/CEO/Pres at HEMISPHERX BIOPHARMA INC (HEB), bought 3,500 shares at $0.20 ($700) on 2018-10-26, disclosed to the SEC on 2018-10-29.
Open-market purchase of $700 HEB by Executive Vice Chairman/CEO/Pres. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| AIM | BUY | 2020-12-17 | $25K | — | Filing → |
| AIM | BUY | 2020-09-03 | $25K | — | Filing → |
| AIM | BUY | 2020-08-21 | $25K | — | Filing → |